FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362620131> ?p ?o ?g. }

• W4362620131 abstract "Two novel series of Schiff bases of 3-(2-aminothiazol-4-yl)-6,8-dichloro-2H-chromen-2- one (SVM 1-11) and 3-(2-aminothiazol-4-yl)-6-nitro-2H-chromen-2-one (SVN 1-11) were synthesized and confirmed by FT-IR, NMR, LC-MS and elemental analysis. The resulting compounds were evaluated for anti-tuberculosis activity using the micro Alamar blue assay (MABA) against susceptible strain H37Rv (ATCC25177) and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB). A computational method was also used to identify the molecular targets for these compounds. Larvicidal and insecticidal activity were evaluated against Anopheles arabiensis using the standard WHO larvicidal assay and cone bioassay methods. Anticancer activity was assessed using the MTT assay against human breast adenocarcinoma cells (MCF-7) and human epithelial lung adenocarcinoma cells (A549). The antioxidant and lipoxygenase inhibitory capacity was measured using the DPPH assay and Lipoxygenase inhibitory kit, respectively. The antimycobacterial efficacy of the synthesized SVM 1-11 showed that SVM 8 and SVM 10 were the most active compounds, with MIC values of 0.5 µg/mL against H37RvMTB and 8 µg/mL against MDR-MTB. Among the synthesized SVN 1-11, the most active compounds were SVN 3 and SVN 4, having MICs of 0.5 and 1 µg/mL against H37Rv-MTB, respectively, and 8 and 4 µg/mL against MDR-MTB. The docking study performed with the target enzymes DprE1and Pks13 indicated that the compounds had a high affinity for the druggable targets DprE1 and Pks13 enzymes of Mycobacterium tuberculosis compared to the reference standards rifampicin and isoniazid. The larvicidal and adulticidal tests revealed that compounds SVM 6 and SVM 9 were the most effective, with larvicidal mortality (100%) equal to the reference drug' Themephos; additionally, the above compounds exhibited significant adulticidal activity of 73.5±1.5 and 77.3±2.3%, respectively. Compounds SVN 6, 7, 8, and 9, on the other hand, were the most potent larvicidal and adulticidal, exhibiting 100% larvae mortality after 24 hours, and significant adulticidal activity. The anticancer activity study indicates that these compounds had a significant effect on MCF-7 cells. SVM 2, 4, 8 and 11 were the most effective with IC50 values ranging from 5.7 to 9.2 µg/mL. Compounds SVN 1, 2, 4, 9, 10, and 11, on the other hand, had a remarkable cytotoxicity effect on MCF-7, with IC50 range from 6.2-16.38 µg/mL. The caspase-Glo® kit test (Caspase 3/7, 8 and 9) was used to assess the mechanism involved in the anticancer activity of the selected active compounds against MCF-7. The results showed that the apoptosis generated by these compounds was triggered in part by the activation of caspase-3/7 and caspase-9, which may be the primary mechanism of apoptosis. The antioxidant results revealed that compounds SVM 3 and SVM 8 were the most potent, with a percentage scavenging capacity of 92.7±1.1 and 89.7±1.7%, respectively. Compounds SVN 5 and 9, on the other hand, were the most active, with a percentage scavenging capacity of 80.5±0.6 and 85.4±1.3%, respectively. The lipoxygenase inhibitory assay revealed that compounds SVM 3, 8, and 11 were the most potent LO inhibitors, with inhibitory capacity ranging from 60 to 67%. Compound SVN 11, on the other hand, was the most effective, with a percentage inhibitory capacity of 61.3±0.3%. Our results suggest that integrating different functional groups on the phenyl ring at the fourth position of the thiazole moiety, connected to the primary coumarin nucleus at the third position, contributed significantly to the biological activity of the compounds. These active compounds could be used as a scaffold for structural optimization to develop highly effective and selective antimycobacterial, anticancer, antioxidant, larvicidal, and adulticidal agents and promote further development of more efficient lipoxygenase inhibitors of novel structurally similar analogues." @default.
• W4362620131 created "2023-04-07" @default.
• W4362620131 creator A5078156693 @default.
• W4362620131 date "2023-04-05" @default.
• W4362620131 modified "2023-09-25" @default.
• W4362620131 title "Synthesis and structural elucidation of novel synthetic coumarin scaffolds for their potential pharmacological properties" @default.
• W4362620131 doi "https://doi.org/10.51415/10321/4702" @default.
• W4362620131 hasPublicationYear "2023" @default.
• W4362620131 type Work @default.
• W4362620131 citedByCount "0" @default.
• W4362620131 crossrefType "dissertation" @default.
• W4362620131 hasAuthorship W4362620131A5078156693 @default.
• W4362620131 hasBestOaLocation W43626201311 @default.
• W4362620131 hasConcept C104488531 @default.
• W4362620131 hasConcept C109316439 @default.
• W4362620131 hasConcept C142724271 @default.
• W4362620131 hasConcept C159110408 @default.
• W4362620131 hasConcept C181199279 @default.
• W4362620131 hasConcept C185592680 @default.
• W4362620131 hasConcept C202751555 @default.
• W4362620131 hasConcept C2777752497 @default.
• W4362620131 hasConcept C2777975735 @default.
• W4362620131 hasConcept C2778004101 @default.
• W4362620131 hasConcept C2779685592 @default.
• W4362620131 hasConcept C2780783641 @default.
• W4362620131 hasConcept C2781069245 @default.
• W4362620131 hasConcept C2781401929 @default.
• W4362620131 hasConcept C41685203 @default.
• W4362620131 hasConcept C54355233 @default.
• W4362620131 hasConcept C55493867 @default.
• W4362620131 hasConcept C71240020 @default.
• W4362620131 hasConcept C71924100 @default.
• W4362620131 hasConcept C86803240 @default.
• W4362620131 hasConcept C98274493 @default.
• W4362620131 hasConceptScore W4362620131C104488531 @default.
• W4362620131 hasConceptScore W4362620131C109316439 @default.
• W4362620131 hasConceptScore W4362620131C142724271 @default.
• W4362620131 hasConceptScore W4362620131C159110408 @default.
• W4362620131 hasConceptScore W4362620131C181199279 @default.
• W4362620131 hasConceptScore W4362620131C185592680 @default.
• W4362620131 hasConceptScore W4362620131C202751555 @default.
• W4362620131 hasConceptScore W4362620131C2777752497 @default.
• W4362620131 hasConceptScore W4362620131C2777975735 @default.
• W4362620131 hasConceptScore W4362620131C2778004101 @default.
• W4362620131 hasConceptScore W4362620131C2779685592 @default.
• W4362620131 hasConceptScore W4362620131C2780783641 @default.
• W4362620131 hasConceptScore W4362620131C2781069245 @default.
• W4362620131 hasConceptScore W4362620131C2781401929 @default.
• W4362620131 hasConceptScore W4362620131C41685203 @default.
• W4362620131 hasConceptScore W4362620131C54355233 @default.
• W4362620131 hasConceptScore W4362620131C55493867 @default.
• W4362620131 hasConceptScore W4362620131C71240020 @default.
• W4362620131 hasConceptScore W4362620131C71924100 @default.
• W4362620131 hasConceptScore W4362620131C86803240 @default.
• W4362620131 hasConceptScore W4362620131C98274493 @default.
• W4362620131 hasLocation W43626201311 @default.
• W4362620131 hasOpenAccess W4362620131 @default.
• W4362620131 hasPrimaryLocation W43626201311 @default.
• W4362620131 hasRelatedWork W1604450252 @default.
• W4362620131 hasRelatedWork W1734425917 @default.
• W4362620131 hasRelatedWork W2002842018 @default.
• W4362620131 hasRelatedWork W2183904007 @default.
• W4362620131 hasRelatedWork W2375457425 @default.
• W4362620131 hasRelatedWork W2765320434 @default.
• W4362620131 hasRelatedWork W2772706031 @default.
• W4362620131 hasRelatedWork W3013997713 @default.
• W4362620131 hasRelatedWork W4221126412 @default.
• W4362620131 hasRelatedWork W4320494718 @default.
• W4362620131 isParatext "false" @default.
• W4362620131 isRetracted "false" @default.
• W4362620131 workType "dissertation" @default.